CX Daily: Lean Times Ahead for Producers of Weight-Loss Drugs

TOP STORIES

In Depth: Lean Times Ahead for Producers of Weight-Loss Drugs

A new class of drugs has transformed weight loss worldwide, for those that can afford it. GLP-1 receptor agonists mimic a gut hormone to boost insulin release, slow digestion and curb hunger.

Since 2023, two firms have turned these drugs into blockbusters.

Novo Nordisk A/S reported first-half revenue of 112.76 billion Danish kroner ($16.35 billion) from semaglutide, sold as a weight-loss injection, diabetes injection and oral tablet. Weight-loss injection sales grew 78%, the fastest among the three.